Nanobiotix's Lead Product Shows Feasibility With No Treatment-Related Toxicity In Pancreatic Cancer Patient
Nanobiotix (NASDAQ: NBTX) has announced the publication of a peer-reviewed case study in Clinical and Translational Radiation Oncology.
Benzinga ·
Benzinga
